Samuel Kintz Sells 5,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $16.42, for a total transaction of $82,100.00. Following the completion of the transaction, the chief executive officer now owns 985,392 shares in the company, valued at $16,180,136.64. The trade was a 0.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Monday, March 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.83, for a total value of $260,375.00.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded down $0.09 during mid-day trading on Friday, reaching $18.21. The stock had a trading volume of 124,974 shares, compared to its average volume of 262,859. The stock's 50 day simple moving average is $19.37 and its two-hundred day simple moving average is $22.70. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.03. The company has a market capitalization of $892.36 million, a price-to-earnings ratio of -9.58 and a beta of 1.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently bought and sold shares of the company. FMR LLC increased its stake in shares of Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after purchasing an additional 199,692 shares during the period. Polar Capital Holdings Plc increased its position in Enliven Therapeutics by 267.6% in the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the period. Vanguard Group Inc. raised its stake in Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock valued at $44,452,000 after acquiring an additional 55,283 shares in the last quarter. Janus Henderson Group PLC boosted its position in Enliven Therapeutics by 27.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after acquiring an additional 290,153 shares during the period. Finally, Pictet Asset Management Holding SA grew its stake in shares of Enliven Therapeutics by 16.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after purchasing an additional 135,969 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.